Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation.
Udgivelsesdato: 2007-Nov-5
Udgivelsesdato: 2007-Nov-5
Bidragets oversatte titel | Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for læger |
Vol/bind | 169 |
Udgave nummer | 45 |
Sider (fra-til) | 3868-71 |
Antal sider | 3 |
ISSN | 0041-5782 |
Status | Udgivet - 2007 |
ID: 8465591